🔗 Share this article

Chancellor Rachel Reeves has stated she is planning "targeted steps to address cost of living pressures" in the forthcoming Budget.

In comments to the BBC, she emphasized that curbing price rises is a shared responsibility of both the government and the Bank of England.

The UK's price growth is projected to be the highest among the G7 developed nations this year and next.

Possible Energy Cost Measures

Reports indicate the administration could take action to bring down energy bills, such as by cutting the current 5% rate of value-added tax charged on energy supplies.

Another approach is to reduce some of the policy costs presently included in household expenses.

Budgetary Constraints and Analyst Expectations

The administration will obtain the next report from the independent fiscal watchdog, the OBR, on Monday, which will clarify how much room there is for these actions.

The expectation from the majority of analysts is that the Chancellor will have to declare tax increases or expenditure reductions in order to fulfill her declared debt limits.

Previously on Thursday, calculations showed there was a £22bn deficit for the chancellor to resolve, which is at the lower end of projections.

"It is a collective job between the Bank of England and the government to continue tackling some of the causes of inflation," Reeves stated to the BBC in Washington, at the yearly gatherings of the International Monetary Fund and World Bank.

Revenue Pledges and International Concerns

While a great deal of the attention has been on expected tax increases, the chancellor said the latest information from the fiscal watchdog had not altered her vow to manifesto promises not to raise rates on earnings tax, sales tax or social security contributions.

She attributed an "unpredictable world" with rising international and commercial tensions for the fiscal tax moves, likely to be targeted on those "with the broadest shoulders."

International Economic Disputes

Commenting on worries about the United Kingdom's commercial links with China she said: "The UK's national security invariably come first."

Recent declaration by China to strengthen trade restrictions on rare earths and other resources that are essential for high-technology manufacturing led US President Donald Trump to threaten an extra 100% import tax on goods from the Asian country, increasing the prospect of an all-out commercial conflict between the two economic giants.

The US Treasury Secretary described China's move "economic coercion" and "a global supply chain control attempt."

Asked about considering the US offer to participate in its dispute with the Asian nation, the Chancellor said she was "extremely troubled" by Chinese measures and encouraged the Beijing authorities "not to put up barriers and limit trade."

She said the decision was "bad for the global economy and creates additional headwinds."

"In my view there are fields where we need to challenge Chinese policies, but there are also significant chances to export to China's economy, including financial services and other areas of the economy. We've got to get that equilibrium right."

The Treasury chief also affirmed she was cooperating with international partners "regarding our own critical minerals plan, so that we are reduced dependence."

NHS Drug Costs and Investment

The Chancellor also admitted that the price the National Health Service pays for drugs could increase as a consequence of ongoing negotiations with the US government and its pharmaceutical firms, in return for reduced taxes and capital.

A number of the biggest global pharmaceutical manufacturers have said in recent statements that they are either halting or canceling investments in the UK, with several attributing the insufficient payments they are obtaining.

Last month, the Science Minister said the price the health service spends on drugs would must increase to stop firms and drug research funding leaving the UK.

Reeves stated to the BBC: "It has been observed due to the payment system, that drug testing, recent pharmaceuticals have not been provided in the UK in the extent that they are in other European countries."

"The objective is to guarantee that people getting treatment from the NHS are able to receive the best essential treatments in the globe. And so we are reviewing these issues, and... aiming to obtain additional capital into the UK."